

## Special Issue

# Epilepsy: Pathogenesis, Treatment, and Precision Medicine

### Message from the Guest Editor

Epilepsy is a chronic disabling neurological disorder that affects people of all ages. Most concern is that over 30% of people with epilepsy will fail medication, so-called **medically intractable** or **drug-resistant**, which will be the focus of this special issue. Individuals with medically intractable seizures have reduced quality of life due to stigma, loss of independence, the cognitive side effects of medication, and recurring seizures. Additionally, the mortality of intractable epilepsy is over 4 times that of age-matched controls. Individuals with medically intractable epilepsy should be evaluated in a comprehensive epilepsy program. Appropriate characterization of epilepsy can improve seizure control as well as identify surgical candidates. In many cases, **surgery** can cure this chronic, disabling, and often deadly neurological disease. Cure from epilepsy significantly elevates the quality of life and erases the increased mortality risk. In this special issue of the JPM, the topics of pathogenesis, treatment, and precision medicine of **medically intractable epilepsy** will be explored. Both original research and review articles are welcome.

### Guest Editor

Prof. Dr. Warren W. Boling

Department of Neurosurgery, Loma Linda University Health, Loma Linda, CA 92354, USA

### Deadline for manuscript submissions

closed (15 April 2023)



## Journal of Personalized Medicine

an Open Access Journal  
by MDPI

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/si/117300](https://mdpi.com/si/117300)

*Journal of Personalized  
Medicine*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[jpm@mdpi.com](mailto:jpm@mdpi.com)

[mdpi.com/journal/](https://mdpi.com/journal/)

[jpm](https://jpm)





# Journal of Personalized Medicine

---

an Open Access Journal  
by MDPI

---

CiteScore 6.0  
Indexed in PubMed



[mdpi.com/journal/  
jpm](https://mdpi.com/journal/jpm)



## About the Journal

### Message from the Editor-in-Chief

*Journal of Personalized Medicine (JPM)*, ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

---

### Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

---

### Author Benefits

#### High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

#### Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).